Discussion stirs around Medtronic plc (NYSE:MDT) this week; here is what analysts are saying.

March 23, 2018 - By Marguerite Chambers

 Discussion stirs around Medtronic plc (NYSE:MDT) this week; here is what analysts are saying.
Investors sentiment increased to 1.12 in 2017 Q3. Its up 0.22, from 0.9 in 2017Q2. It improved, as 73 investors sold Medtronic plc shares while 392 reduced holdings. 109 funds opened positions while 414 raised stakes. 1.07 billion shares or 1.07% more from 1.06 billion shares in 2017Q2 were reported.
Rhenman Asset Mgmt holds 2.13% of its portfolio in Medtronic plc (NYSE:MDT) for 214,115 shares. Gulf Interest Retail Bank (Uk) Ltd holds 0.45% of its portfolio in Medtronic plc (NYSE:MDT) for 434,019 shares. Stonebridge Advisors Limited Liability invested in 8,044 shares. Ogorek Anthony Joseph New York Adv invested in 8,200 shares. High Pointe Cap Mngmt Ltd Llc stated it has 1.78% of its portfolio in Medtronic plc (NYSE:MDT). Middleton And Co Inc Ma reported 7,005 shares. Counselors Inc owns 90,027 shares for 0.34% of their portfolio. Moreover, Haverford Trust has 1.73% invested in Medtronic plc (NYSE:MDT). Nj State Employees Deferred Compensation Plan holds 20,000 shares. 2.64M were accumulated by Vontobel Asset Mgmt Incorporated. Public Sector Pension Invest Board accumulated 0.09% or 266,326 shares. Calamos Wealth Management Limited Liability has invested 0.07% in Medtronic plc (NYSE:MDT). Griffin Asset Mngmt Incorporated holds 30,371 shares. Bailard Inc reported 0.39% in Medtronic plc (NYSE:MDT). Mayo Inv Advisers Ltd Liability Co owns 67,558 shares.

Medtronic plc (NYSE:MDT) Ratings Coverage

Among 28 analysts covering Medtronic (NYSE:MDT), 18 have Buy rating, 0 Sell and 10 Hold. Therefore 64% are positive. Medtronic had 81 analyst reports since August 10, 2015 according to SRatingsIntel. Guggenheim initiated the shares of MDT in report on Thursday, June 9 with “Neutral” rating. Citigroup maintained the stock with “Buy” rating in Thursday, February 22 report. SunTrust maintained Medtronic plc (NYSE:MDT) rating on Friday, November 17. SunTrust has “Buy” rating and $92.0 target. Stifel Nicolaus maintained the shares of MDT in report on Tuesday, August 22 with “Hold” rating. The company was maintained on Wednesday, November 23 by Needham. The firm earned “Buy” rating on Thursday, March 17 by Nomura. The firm has “Buy” rating given on Friday, August 26 by Jefferies. The stock of Medtronic plc (NYSE:MDT) has “Buy” rating given on Tuesday, August 23 by Citigroup. On Monday, February 5 the stock rating was maintained by Morgan Stanley with “Equal-Weight”. The company was reinitiated on Monday, August 10 by Credit Suisse. Below is a list of Medtronic plc (NYSE:MDT) latest ratings and price target changes.

22/02/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $100 New Target: $93 Maintain
21/02/2018 Broker: Needham Rating: Buy New Target: $95.0 Maintain
05/02/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $91 New Target: $95 Maintain
03/01/2018 Broker: Evercore Rating: Outperform New Target: $92.5 Initiates Coverage On
02/01/2018 Broker: Bank of America Old Rating: Neutral New Rating: Buy Upgrade
12/12/2017 Broker: Argus Research Rating: Buy New Target: $95.0 Upgrade
12/12/2017 Broker: BMO Capital Markets Rating: Buy New Target: $94.0 Maintain
21/11/2017 Broker: Jefferies Rating: Buy New Target: $99.0 Maintain
22/11/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $85.0 Maintain
21/11/2017 Broker: Needham Rating: Buy New Target: $95.0 Maintain

The stock increased 0.35% or $0.28 during the last trading session, reaching $78.42. About 2.54M shares traded. Medtronic plc (NYSE:MDT) has risen 4.04% since March 23, 2017 and is uptrending. It has underperformed by 12.66% the S&P500.

Medtronic plc manufactures and sells device medical therapies to hospitals, physicians, clinicians, and patients worldwide. The company has market cap of $106.28 billion. The companyÂ’s Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; diagnostics and monitoring devices; mechanical circulatory support, TYRX, and AF products; and remote monitoring and patient-centered software. It has a 38.36 P/E ratio. It also provides transcatheter heart valves, percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, peripheral vascular products, and products to treat superficial and deep venous diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.